Inhibition of IL-1β by Canakinumab reduces MACE rates in high risk CKD patients

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Inhibition of IL-1β by Canakinumab reduces MACE rates in high risk CKD patients

posted on May 24, 2018 08:18PM

Looks like in a sub-study of Paul Ridker's CANTOS study (anti-interleukin-1B antibody) published in the May issue of Journal of the American College of Cardiolgy, that CKD patients with a robust anti-inflammatory response to Canakinumab treatment (to below hsCRP <2 mg/l) showed a strong reduction (27% to 39% RRR) in MACE, cardiovascular mortality and all cause mortality. I don't have access to the full article, but here is a link to the abstract and a figure that speaks for itself!

Note, Canakinumab has no effect on eGFR. Imagine what apabetalone can do by not only being anti-inflammatory, but also improving eGFR, reducing alkaline phosphatase, raising apoAI/HDL, etc!